Development and preliminary validation of the patient-reported Chronic Itch Burden Scale assessing health-related quality of life in chronic pruritus.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
accepted:
13
06
2021
pubmed:
16
6
2021
medline:
4
3
2022
entrez:
15
6
2021
Statut:
ppublish
Résumé
Chronic pruritus (CP) significantly affects patients' health-related quality of life (HRQoL). Very few self-reported HRQoL questionnaires exploring CP have been developed according to international guidelines, thus limiting their use in preauthorization trials. To develop a self-reported HRQoL questionnaire in patients with CP owing to psoriasis, atopic dermatitis, seborrhoeic dermatitis of the scalp or idiopathic dermatitis, and to explore the preliminary psychometric properties of the questionnaire. The study was performed in France. A conceptual framework was developed based on a structured literature review and expert insight, and was improved using three focus groups involving 19 participants. A 50-item questionnaire was created and tested with 21 participants using cognitive debriefings; 11 items were removed. A cross-sectional study including 251 participants was performed to explore the preliminary psychometric properties of the 39-item questionnaire. Dimensionality was explored using principal component analysis. Cronbach's alpha and correlation coefficients (interitem, item-total score and item-dimension score) were measured. The number of items was reduced through expert consensus. In the 39-item version, three main dimensions were identified (Cronbach's alpha = 0·94) and all correlation coefficients were > 0·34. Upon review, 13 items were deleted owing to poor quality and six items were deleted by the team, generating a 20-item version. The questionnaire's factorial structure was best reflected with a two-dimension solution, i.e. (i) social and emotional repercussions and (ii) relation to others, fear of judgement. The Chronic Itch Burden Scale patient-reported questionnaire explores broad aspects of HRQoL that are relevant for patients with various skin diseases. Its good cross-sectional validity makes it useful for trials and practitioners.
Sections du résumé
BACKGROUND
Chronic pruritus (CP) significantly affects patients' health-related quality of life (HRQoL). Very few self-reported HRQoL questionnaires exploring CP have been developed according to international guidelines, thus limiting their use in preauthorization trials.
OBJECTIVES
To develop a self-reported HRQoL questionnaire in patients with CP owing to psoriasis, atopic dermatitis, seborrhoeic dermatitis of the scalp or idiopathic dermatitis, and to explore the preliminary psychometric properties of the questionnaire.
METHODS
The study was performed in France. A conceptual framework was developed based on a structured literature review and expert insight, and was improved using three focus groups involving 19 participants. A 50-item questionnaire was created and tested with 21 participants using cognitive debriefings; 11 items were removed. A cross-sectional study including 251 participants was performed to explore the preliminary psychometric properties of the 39-item questionnaire. Dimensionality was explored using principal component analysis. Cronbach's alpha and correlation coefficients (interitem, item-total score and item-dimension score) were measured. The number of items was reduced through expert consensus.
RESULTS
In the 39-item version, three main dimensions were identified (Cronbach's alpha = 0·94) and all correlation coefficients were > 0·34. Upon review, 13 items were deleted owing to poor quality and six items were deleted by the team, generating a 20-item version. The questionnaire's factorial structure was best reflected with a two-dimension solution, i.e. (i) social and emotional repercussions and (ii) relation to others, fear of judgement.
CONCLUSIONS
The Chronic Itch Burden Scale patient-reported questionnaire explores broad aspects of HRQoL that are relevant for patients with various skin diseases. Its good cross-sectional validity makes it useful for trials and practitioners.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-95Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 British Association of Dermatologists.
Références
Stander S, Weisshaar E, Mettang T et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87:291-4.
Matterne U, Apfelbacher CJ, Vogelgsang L et al. Incidence and determinants of chronic pruritus: a population-based cohort study. Acta Derm Venereol 2013; 93:532-7.
Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol 2018; 14 (Suppl. 2):52.
Valdes-Rodriguez R, Stull C, Yosipovitch G. Chronic pruritus in the elderly: pathophysiology, diagnosis and management. Drugs Aging 2015; 32:201-15.
Pereira MP, Hoffmann V, Weisshaar E et al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol 2020; 34:2373-83.
Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 2009; 89:339-50.
Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-4.
Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investig Dermatol 2015; 3:10.
Ständer S, Augustin M, Reich A et al. Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol 2013; 93:509-14.
Chrostowska-Plak D, Salomon J, Reich A, Szepietowski JC. Clinical aspects of itch in adult atopic dermatitis patients. Acta Derm Venereol 2009; 89:379-83.
Weisshaar E, Gieler U, Kupfer J et al. Questionnaires to assess chronic itch: a consensus paper of the special interest group of the International Forum on the Study of Itch. Acta Derma Venereol 2012; 92:493-6.
Furue M, Ebata T, Ikoma A et al. Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. Acta Derm Venereol 2013; 93:214-15.
Naegeli AN, Flood E, Tucker J et al. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol 2015; 54:715-22.
Phan NQ, Blome C, Fritz F et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92:502-7.
Reich A, Heisig M, Phan NQ et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92:497-501.
Marron SE, Tomas-Aragones L, Boira S, Campos-Rodenas R. Quality of life, emotional wellbeing and family repercussions in dermatological patients experiencing chronic itching: a pilot study. Acta Derm Venereol 2016; 96:331-5.
Weisshaar E, Apfelbacher C, Jager G et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol 2006; 155:957-64.
Carr CW, Veledar E, Chen SC. Factors mediating the impact of chronic pruritus on quality of life. JAMA Dermatol 2014; 150:613-20.
Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol 2010; 162:587-93.
Szepietowski JC, Schwartz RA. Uremic pruritus. Int J Dermatol 1998; 37:247-53.
Al-Qarqaz FA, Al Aboosi M, Al-Shiyab D, Bataineh A. Using pruritus grading system for measurement of pruritus in patients with diseases associated with itch. Jordan Med J 2012; 46:39-44.
Yosipovitch G, Zucker I, Boner G et al. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol 2001; 81:108-11.
Darsow U, Scharein E, Simon D et al. New aspects of itch pathophysiology: component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire’. Int Arch Allergy Immunol 2001; 124:326-31.
Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. Br J Dermatol 2007; 156:667-73.
Desai NS, Poindexter GB, Monthrope YM et al. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol 2008; 59:234-44.
Dauden E, Sanchez-Perez J, Prieto M, Roset M. [Validation of the Spanish Version of the Itch Severity Scale: the PSEDA Study]. Actas Dermosifiliogr 2011; 102:527-36 (in Spanish).
Zachariae R, Lei U, Haedersdal M, Zachariae C. Itch severity and quality of life in patients with pruritus: preliminary validity of a Danish adaptation of the itch severity scale. Acta Derm Venereol 2012; 92:508-14.
Reich A, Bozek A, Janiszewska K, Szepietowski JC. 12-Item Pruritus Severity Scale: development and validation of new itch severity questionnaire. Biomed Res Int 2017; 2017:3896423.
Amatya B, Nordlind K. Focus groups in Swedish psoriatic patients with pruritus. J Dermatol 2008; 35:1-5.
Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes 2009; 7:62.
Dominick F, van Laarhoven A, Evers A, Weisshaar E. A systematic review of questionnaires on itch by the Special Interest Group “Questionnaires” of the International Forum for the Study of Itch (IFSI). Itch 2019; 4:e26.
US Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims (last accessed 2 March 2015).
Patrick DL, Burke LB, Gwaltney CJ et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1-eliciting concepts for a new PRO instrument. Value Health 2011; 14:967-77.
Patrick DL, Burke LB, Gwaltney CJ et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2-assessing respondent understanding. Value Health 2011; 14:978-88.
European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. (Pre-authorisation evaluation of medicines for human use). London: European Medicines Agency, 2005.
Morse JM, Field PA. Qualitative Research Methods for Health Professionals. Thousand Oaks, CA: SAGE Publications Inc., 1995.
Morgan DL. Qualitative content analysis: a guide to paths not taken. Qual Health Res 1993; 3:112-21.
Rouquette A, Falissard B. Sample size requirements for the internal validation of psychiatric scales. Int J Methods Psychiatr Res 2011; 20:235-49.
Zwick WR, Velicer WF. Comparison of five rules for determining the number of components to retain. Psychol Bull 1986; 99:432-42.
Cattell RB. The scree test for the number of factors. Multivariate Behav Res 1966; 1:245-76.
Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16:297-334.
Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971; 76:378-82.
COSMIN. Guideline for systematic reviews of outcome measurement instruments. Available at: https://www.cosmin.nl/tools/guideline-conducting-systematic-review-outcome-measures/?portfolioCats=19. (last accessed 21 April 2021).
Bathe A, Weisshaar E, Matterne U. Chronic pruritus-more than a symptom: a qualitative investigation into patients’ subjective illness perceptions. J Adv Nurs 2013; 69:316-26.
Beynon T, Selman L, Radcliffe E et al. ‘We had to change to single beds because I itch in the night’: a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma. Br J Dermatol 2015; 173:83-92.
Kimball AB, Naegeli AN, Edson-Heredia E et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175:157-62.
Chrostowska-Plak D, Reich A, Szepietowski JC. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2013; 27:e239-42.
Acar B, Karabulut H, Sahin Y et al. New treatment strategy and assessment questionnaire for external auditory canal pruritus: topical pimecrolimus therapy and Modified Itch Severity Scale. J Laryngol Otol 2010; 124:147-51.
Bushmakin AG, Mamolo C, Cappelleri JC, Stewart M. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat 2015; 26:19-22.
Balaskas EV, Chu M, Uldall RP et al. Pruritus in continuous ambulatory peritoneal dialysis and hemodialysis patients. Perit Dial Int 1993; 13 (Suppl. 2):S527-32.
Beuers U, Jones DE, Mayo MJ et al. Fxr agonist obeticholic acid: Pruritus, a common side effect ameliorated by dose titration. Hepatology 2014; 60:356A-7A.
Krause K, Kessler B, Weller K et al. German version of ItchyQoL: validation and initial clinical findings. Acta Derm Venereol 2013; 93:562-8.
Love EM, Marrazzo GA, Kini S et al. ItchyQoL bands: pilot clinical interpretation of scores. Acta Derm Venereol 2015; 95:114-15.
Blome C, Augustin M, Siepmann D et al. Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol 2009; 161:1143-8.
Erturk IE, Arican O, Omurlu IK, Sut N. Effect of the pruritus on the quality of life: a preliminary study. Ann Dermatol 2012; 24:406-12.
Gauffin E, Oster C, Gerdin B, Ekselius L. Prevalence and prediction of prolonged pruritus after severe burns. J Burn Care Res 2015; 36:405-13.
Bosecker P, Staender S, Heuft G et al. [Conception and evaluation of an 1-hour psychoeducational group intervention for patients with chronic pruritus]. Z Psychosom Med Psychother 2011; 57:377-86 (in German).
Huizinga J, van Os-Medendorp H, Ros WJ et al. Validation of the Dutch version of the itching cognitions questionnaire. J Nurs Meas 2012; 20:35-46.
Ehlers A, Stangier U, Dohn D, Gieler U. Kognitive faktoren beim juckreiz: entwicklung und validierung eines fragebogens [Cognitive factors in itching: development and validation of a questionnaire]. Verhaltenstherapie 1993; 3:112-19. (in German).
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16.
Evers AWM, Duller P, van de Kerkhof PCM et al. The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol 2008; 158:101-8.
Duque MI, Thevarajah S, Chan YH et al. Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clinl Nephrol 2006; 66:184-91.
Duque MI, Yosipovitch G, Chan YH et al. Itch, pain, and burning sensation are common symptoms in mild to moderate chronic venous insufficiency with an impact on quality of life. J Am Acad Dermatol 2005; 53:504-8.
Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation. Allergy 2009; 64:581-8.
Choi WS, Lim ES, Ban GY et al. Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria. Korean J Intern Med 2018; 33:185-92.
Yosipovitch G, Goon AT, Wee J et al. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol 2002; 41:212-6.
Aguilar-Hinojosa NK, Segura-Méndez NH, Lugo-Reyes SO. Correlación de la gravedad de urticaria crónica y calidad de vida. [Correlation of severity of chronic urticaria and quality of life]. Rev Alerg Mex 2012; 59:180-6 (in Spanish).
Stumpf A, Stander S, Warlich B et al. Relations between the characteristics and psychological comorbidities of chronic pruritus differ between men and women: women are more anxious than men. Br J Dermatol 2015; 172:1323-8.
Dalgard F, Lien L, Dalen I. Itch in the community: associations with psychosocial factors among adults. J Eur Acad Dermatol Venereol 2007; 21:1215-19.
Amatya B, Wennersten G, Nordlind K. Patients’ perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol 2008; 22:822-6.
Blome C, Radtke MA, Eissing L, Augustin M. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol 2016; 17:163-9.
Danial C, Adeduntan R, Gorell ES et al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol 2015; 32:53-9.
Verhoeven EWM, Kraaimaat FW, van de Kerkhof PC et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 2007; 156:1346-9.
Depenau C, Schroder R, Osada N et al. [Pain and pruritus: differences and similarities as revealed by the PainDetect questionnaire parameters]. Hautarzt 2012; 63:539-46 (in German).
Dalgard F, Dawn AG, Yosipovitch G. Are itch and chronic pain associated in adults? Results of a large population survey in Norway. Dermatology 2007; 214:305-9.
Afsar B, Elsurer Afsar R. HbA1c is related with uremic pruritus in diabetic and nondiabetic hemodialysis patients. Ren Fail 2012; 34:1264-9.
Czarnecka-Operacz M, Polanska A, Klimanska M et al. Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations. Postepy Dermatol Alergol 2015; 32:426-30.
Dalgard F, Stern R, Lien L, Hauser S. Itch, stress and self-efficacy among 18-year-old boys and girls: a Norwegian population-based cross-sectional study. Acta Derm Venereol 2012; 92:547-52.
Stumpf A, Ständer S, Phan NQ et al. Body concept of patients with chronic pruritus in relation to scratch lesions and psychic symptoms. Dermatology 2013; 227:263-9.
Zeidler C, Steinke S, Riepe C et al. Cross-European validation of the ItchyQoL in pruritic dermatoses. J Eur Acad Dermatol Venereol 2019; 33:391-7.
Schoch D, Sommer R, Augustin M et al. Patient-reported outcome measures in pruritus: a systematic review of measurement properties. J Invest Dermatol 2017; 137:2069-77.
Sanders KM, Akiyama T. The vicious cycle of itch and anxiety. Neurosci Biobehav Rev 2018; 87:17-26.
van Beugen S, van Middendorp H, Ferwerda M et al. Predictors of perceived stigmatization in patients with psoriasis. Br J Dermatol 2017; 176:687-94.
Barbarot S, Auziere S, Gadkari A et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 2018; 73:1284-93.
Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish register patients. Am J Clin Dermatol 2017; 18:583-90.